Ryan D. Stultz

Ryan D. Stultz

Auto-generated profile, based on publicly available information

Ryan D. Stultz

Division of Rheumatology, University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2025 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
RSRd Stultz
Rd Stultz
LDL Dai
L Dai
EGE van Geel
E van Geel
MGM Gerritsen
M Gerritsen
MNM.T. Nurmohamed
M.T. Nurmohamed
CLChristian Lood
Christian Lood
Although gout is the most common inflammatory arthritis, there are few tools to monitor disease activity and predict complications in gout patients. The neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) are associated with disease activity in various diseases and the NLR has been shown to predict coronary artery disease severity, a common comorbid condition with gout. Thus, we evaluated the use of NLR and MLR as novel biomarkers to measure disease activity and predict cardiovascular disease (CVD) risk in gout patients. Data were collected from 38 gout patients. Disease activity, including total number of acute gout attacks, and 10 year risk of cardiovascular morbidity, were assessed at the patient's visit. Calprotectin, cell counts, and uric acid levels were measured from patients' blood. Levels of the neutrophil activation marker calprotectin correlated with NLR (r = 0.56, p = 0.0004). MLR correlated with total number of gout attacks as well (r = 0.39, p = 0.02). NLR and MLR, but not absolute monocyte or neutrophil counts, were significantly correlated with body mass index and significantly increased in gout patients with high CVD risk (p < 0.05). Using logistic regression analysis, patients with high NLR or MLR (defined as the upper quartile of patients) had increased odds of developing high CVD risk (odds ratio 7.5, 95% confidence interval 1.7-33.0). NLR and MLR are potential biomarkers to predict gout flare risk. An increase in either may indicate an increased risk of CVD morbidity.

21 November 2025 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
ICIrene Carrión-Barberá
Irene Carrión-Barberá
CLChristian Lood
Christian Lood
RSRyan D. Stultz
Ryan D. Stultz
JTJenna Thomason
Jenna Thomason
ABAlison M. Bays
Alison M. Bays